Reduced peroxisome proliferator-activated receptor α expression is associated with decreased survival and increased tissue bacterial load in sepsis

Shock

Volumn 37, Issue 2, 2012, Pages 164-169

  Standage, Stephen W ^a   Caldwell, Charles C ^b   Zingarelli, Basilia ^a   Wong, Hector R ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

bacterial load; nuclear hormone receptors; Pediatric sepsis; PPAR ; septic shock

Indexed keywords

CELL SURFACE MARKER; CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL LOAD; BLOOD ANALYSIS; CD8+ T LYMPHOCYTE; CECUM; CELL ACTIVATION; CHILD; CONTROLLED STUDY; DENDRITIC CELL; DISEASE SEVERITY; EXPERIMENTAL LIGATION; FEMALE; HUMAN; INFANT; KERATINOCYTE; KNOCKOUT MOUSE; LUNG PARENCHYMA; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRESCHOOL CHILD; PROTEIN EXPRESSION; PUNCTURE; SCHOOL CHILD; SEPSIS; SEPTIC SHOCK; SPLEEN; SPLEEN CELL; SURVIVAL; WILD TYPE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFANT; KERATINOCYTES; LUNG; MALE; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; PPAR ALPHA; SEPSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856172639     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31823f1a00     Document Type: Article

References (36)

1. Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature 405(6785):421-424, 2000. (Pubitemid 30367411)
2. Lee C-H, Olson P, Evans RM: Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144(6): 2201-2207, 2003. (Pubitemid 36629867)
3. FerréP: The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53(Suppl 1): S43-S50, 2004.
4. Brown JD, Plutzky J: Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115(4):518-533, 2007. (Pubitemid 46184203)
5. Kota BP, Huang TH-W, Roufogalis BD: An overview on biological mechanisms of PPARs. Pharmacol Res 51(2):85-94, 2005. (Pubitemid 40040538)
6. Bailey ST, Ghosh S: BPPAR[ting ways with inflammation. Nat Immunol 6(10):966-967, 2005.
7. Glass CK, Ogawa S: Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 6(1):44-55, 2006. (Pubitemid 43279752)
8. Michalik L, Wahli W: Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest 116(3):598-606, 2006. (Pubitemid 43326864)
9. Bensinger SJ, Tontonoz P: Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454(7203):470-477, 2008.
10. Wong HR, Shanley TP, Sakthivel B, Cvijanovich N, Lin R, Allen GL, Thomas NJ, Doctor A, Kalyanaraman M, Tofil NM, et al.: Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome. Physiol Genomics 30(2):146-155, 2007. (Pubitemid 47173278)
11. Wong HR, Cvijanovich N, Lin R, Allen GL, Thomas NJ, Willson DF, Freishtat RJ, Anas N, Meyer K, Checchia PA, et al.: Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med 7:34, 2009.
12. Wong HR, Cvijanovich N, Allen GL, Lin R, Anas N, Meyer K, Freishtat RJ, Monaco M, Odoms K, Sakthivel B, et al.: Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum. Crit Care Med 37(5):1558-1566, 2009.
13. Wong HR, Freishtat RJ, Monaco M, Odoms K, Shanley TP: Leukocyte subsetderived genomewide expression profiles in pediatric septic shock. Pediatr Crit Care Med 11(3):349-355, 2010.
14. Goldstein B, Giroir B, Randolph A: International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 6(1):2-8, 2005.
15. Shanley TP, Cvijanovich N, Lin R, Allen GL, Thomas NJ, Doctor A, Kalyanaraman M, Tofil NM, Penfil S, Monaco M, et al.: Genome-level longitudinal expression of signaling pathways and gene networks in pediatric septic shock. Mol Med 13(9-10):495-508, 2007. (Pubitemid 47585744)
16. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW 3rd, Bland KI, Chaudry IH: Cecal ligation and puncture. Shock 24(Suppl 1):52-57, 2005.
17. Caldwell CC, Kojima H, Lukashev D, Armstrong J, Farber M, Apasov SG, Sitkovsky MV: Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. J Immunol 167(11):6140-6149, 2001. (Pubitemid 33081540)
18. Madrazo JA, Kelly DP: The PPAR trio: regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol 44(6):968-975, 2008.
19. Odegaard JI, Chawla A: Mechanisms of macrophage activation in obesityinduced insulin resistance. Nat Clin Pract Endocrinol Metab 4(11):619-626, 2008.
20. Olefsky JM, Glass CK: Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72:219-246, 2010.
21. Lumeng CN, Saltiel AR: Inflammatory links between obesity and metabolic disease. J Clin Invest 121(6):2111-2117, 2011.
22. Cunard R, DiCampli D, Archer DC, Stevenson JL, Ricote M, Glass CK, Kelly CJ: WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J Immunol 169(12):6806-6812, 2002. (Pubitemid 36899265)
23. Di Paola R, Esposito E, Mazzon E, Genovese T, Muià C, Crisafulli C, Malleo G, Sessa E, Meli R, Cuzzocrea S: Absence of peroxisome proliferatorsactivated receptors (PPAR) alpha enhanced the multiple organ failure induced by zymosan. Shock 26(5):477-484, 2006. (Pubitemid 44632277)
24. Yang Y, Gocke AR, Lovett-Racke A, Drew PD, Racke MK: PPAR alpha regulation of the immune response and autoimmune encephalomyelitis. PPAR Res 2008:546753, 2008.
25. Smeets PJH, Teunissen BEJ, Planavila A, de Vogel-van den Bosch H, Willemsen PHM, van der Vusse GJ, van Bilsen M: Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta. J Biol Chem 283(43):29109-29118, 2008.
26. Schaefer MB, Pose A, Ott J, Hecker M, Behnk A, Schulz R, Weissmann N, Günther A, Seeger W, Mayer K: Peroxisome proliferator-activated receptoralpha reduces inflammation and vascular leakage in a murine model of acute lung injury. Eur Respir J 32(5):1344-1353, 2008.
27. Patel NSA, di Paola R, Mazzon E, Britti D, Thiemermann C, Cuzzocrea S: Peroxisome proliferator-activated receptor-alpha contributes to the resolution of inflammation after renal ischemia/reperfusion injury. J Pharmacol Exp Ther 328(2):635-643, 2009.
28. Riccardi L, Mazzon E, Bruscoli S, Esposito E, Crisafulli C, Di Paola R, Caminiti R, Riccardi C, Cuzzocrea S: Peroxisome proliferator-activated receptor-alpha modulates the anti-inflammatory effect of glucocorticoids in a model of inflammatory bowel disease in mice. Shock 31(3):308-316, 2009.
29. Gocke AR, Hussain RZ, Yang Y, Peng H, Weiner J, Ben L-H, Drew PD, Stuve O, Lovett-Racke AE, Racke MK: Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease. J Immunol 182(7):4479-4487, 2009.
30. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 348(2):138-150, 2003. (Pubitemid 36056721)
31. Ward NS, Casserly B, Ayala A: The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med 29(4):617-625, viii, 2008.
32. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA: The sepsis seesaw: tilting toward immunosuppression. Nat Med 15(5):496-497, 2009.
33. Zingarelli B, Sheehan M, Hake PW, O'Connor M, Denenberg A, Cook JA: Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy- Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 171(12):6827-6837, 2003. (Pubitemid 37532118)
34. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferatoractivated receptor-gamma is a negative regulator of macrophage activation. Nature 391(6662):79-82, 1998. (Pubitemid 28079218)
35. Zingarelli B, Cook JA: Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 23(5):393-399, 2005. (Pubitemid 40571660)
36. Straus DS, Glass CK: Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 28(12):551-558, 2007. (Pubitemid 350101420)